GlassScriptPhysician profile
Pradeep S Prasad
NPI 1639348204
$77,040.41
in general payments reported to CMS, 2019-2025
20 companies · $29K in 2025
The $29K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,226 · 2020: $5,170 · 2021: $3,621 · 2022: $2,832 · 2023: $4,221 · 2024: $26K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Consulting Fee: $4,900 · Food and Beverage: $4,764 · Travel and Lodging: $1,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,605.44 |
| Consulting Fee | $4,900.00 |
| Food and Beverage | $4,764.43 |
| Travel and Lodging | $1,922.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $50,087.80 | 2019-2025 | Eylea Hd, Eylea |
| Dutch Ophthalmic, USA | $8,494.17 | 2019-2025 | Tissueblue, Eva, Combined Machine |
| Abbvie INC. | $5,454.55 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $3,892.85 | 2019-2021 | |
| Alimera Sciences, INC. | $3,429.27 | 2019-2022 | |
| Genentech, INC. | $2,000.00 | 2020 | |
| Alcon Vision LLC | $1,074.71 | 2019-2021 | |
| Astellas Pharma US INC | $598.95 | 2023-2025 | Izervay |
| Allergan, INC. | $533.05 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $525.35 | 2022-2025 | Syfovre |
| Genentech USA, INC. | $276.87 | 2023-2024 | Vabysmo |
| Carl Zeiss Meditec USA, INC. | $167.73 | 2024 | Quatera 700, Iolmaster 700 |
| Bausch & Lomb Americas INC. | $128.31 | 2025 | Stellaris |
| Aquestive Therapeutics, INC. | $127.90 | 2019 | |
| Sunovion Pharmaceuticals INC. | $116.72 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $113.85 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.33 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradeep Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.